{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fludrocortisone%2F+Fludrocortisone+acetate", "query": { "intervention": "Fludrocortisone/ Fludrocortisone acetate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fludrocortisone%2F+Fludrocortisone+acetate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T04:55:43.395Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03436485", "title": "Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "ODM-208", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orion Corporation, Orion Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 204, "start_date": "2018-03-19", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-30T04:55:43.395Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Minneapolis, Minnesota • Omaha, Nebraska + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03436485" }, { "nct_id": "NCT00001521", "title": "Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Congenital Adrenal Hyperplasia (CAH)" ], "interventions": [ { "name": "Fludrocortisone", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Flutamide", "type": "DRUG" }, { "name": "Testolactone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 66, "start_date": "1995-06-08", "completion_date": "2024-04-01", "has_results": true, "last_update_posted_date": "2025-06-12", "last_synced_at": "2026-09-30T04:55:43.395Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001521" }, { "nct_id": "NCT06136624", "title": "Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Opevesostat", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Fludrocortisone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1310, "start_date": "2023-12-31", "completion_date": "2030-02-15", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-30T04:55:43.395Z", "location_count": 48, "location_summary": "Orange, California • Palo Alto, California • Riverside, California + 41 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Highlands Ranch", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06136624" }, { "nct_id": "NCT01186185", "title": "Fludrocortisone for Sudden Hearing Loss", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hearing Loss, Sensorineural" ], "interventions": [ { "name": "Fludrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 5, "start_date": "2012-08", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2019-10-18", "last_synced_at": "2026-09-30T04:55:43.395Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186185" }, { "nct_id": "NCT06633419", "title": "A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Opevesostat", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Fludrocortisone acetate", "type": "DRUG" }, { "name": "Carbamazepine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 14, "start_date": "2024-12-18", "completion_date": "2025-05-13", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-09-30T04:55:43.395Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06633419" }, { "nct_id": "NCT06801236", "title": "Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer (Adenocarcinoma)", "mCRPC (Metastatic Castration-resistant Prostate Cancer)" ], "interventions": [ { "name": "ACE-232 tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerand Therapeutics (Hong Kong) Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 88, "start_date": "2025-05-12", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-30T04:55:43.395Z", "location_count": 8, "location_summary": "La Jolla, California • Tampa, Florida • Baltimore, Maryland + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06801236" }, { "nct_id": "NCT06609005", "title": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "INV-9956", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shenzhen Ionova Life Sciences Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 84, "start_date": "2025-01-23", "completion_date": "2028-01-17", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-30T04:55:43.395Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Newport Beach, California • Orange, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06609005" }, { "nct_id": "NCT03710187", "title": "HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Septic Shock" ], "interventions": [ { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Tennessee Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2018-11-05", "completion_date": "2019-09-27", "has_results": true, "last_update_posted_date": "2021-05-20", "last_synced_at": "2026-09-30T04:55:43.395Z", "location_count": 1, "location_summary": "Knoxville, Tennessee", "locations": [ { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03710187" }, { "nct_id": "NCT03548246", "title": "Androgen Reduction in Congenital Adrenal Hyperplasia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Congenital Adrenal Hyperplasia" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Fludrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "9 Years", "sex": "ALL", "summary": "2 Years to 9 Years" }, "enrollment_count": 0, "start_date": "2023-01", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-09-30T04:55:43.395Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03548246" }, { "nct_id": "NCT02574910", "title": "Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Congenital Adrenal Hyperplasia" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "9 Years", "sex": "ALL", "summary": "2 Years to 9 Years" }, "enrollment_count": 4, "start_date": "2017-08-01", "completion_date": "2023-06-03", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-09-30T04:55:43.395Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02574910" } ] }